VCX Fundrise Innovation Fund, LLC Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
04:05
Aug 28
Aug 28
Long DXYZ VCX NSLR into Ant IPO
Buy DXYZ, VCX, NSLR as a self-described braindead retail-style trade into the Ant IPO, seeking a 3x move.
MED
03:58
Aug 28
Aug 28
Author frames biotech software as his biggest AI bet but lists it as a speculative watchlist.
Author frames biotech software as his biggest AI bet but lists it as a speculative watchlist without explicit position markers or price targets.
LOW
02:54
Aug 21
Aug 21
Buy CEF wrappers DXYZ/VCX/NSLR on Anthropic S-1
Buy DXYZ/VCX/NSLR as wrapper CEFs that should benefit most when Anthropic goes public; NSLR adds OpenAI-beta optionality.
MED
01:29
Aug 20
Aug 20
Author flags three low-liquidity vehicles as best asymmetric exposure to the OpenAI IPO.
Author flags three low-liquidity vehicles as best asymmetric exposure to the OpenAI IPO but cannot size big, so this is a watchlist not a position.
LOW
23:06
Aug 13
Aug 13
Author lists four tickers without any directional commentary or position disclosure.
Author lists four tickers without any directional commentary or position disclosure, so they are indexed as watch items only.
LOW
17:27
Aug 13
Aug 13
VCX 4x unlock, no borrow, IPO catalysts
Reports $VCX unlock of ~4x float tomorrow, no shares left to borrow on IBKR, 1.1x mNAV, with OpenAI/Ant IPO catalysts ahead; no clear directional stance.
LOW
17:26
Aug 13
Aug 13
Author frames the unlock as a bullish setup with no borrowable shares.
Author frames the unlock as a bullish setup with no borrowable shares, upcoming OpenAI and Ant IPOs, and cheap valuation, calling it "le bullish unlock."
06:32
Aug 13
Aug 13
Author sarcastically flags these tickers as potentially ruinous trades without stating.
Author sarcastically flags these tickers as potentially ruinous trades without stating a position or direction, so they are indexed as watch.
LOW
14:38
Jun 16
Jun 16
Short VCX as author sees current market conditions as near peak mania for junk/speculative.
Short VCX as author sees current market conditions as near peak mania for junk/speculative stocks, with elevated short exposure to frothy names as a tactical theme.
MED
17:00
Jun 11
Jun 11
VCX overvalued; lockup expiry to compress NAV.
VCX is a closed-end fund holding stakes in SpaceX, Anthropic, and other pre-IPO companies. It trades at an extreme premium to NAV (11x NAV even after adjusting for higher valuations of holdings). A six-month IPO lockup expires in September, which will likely trigger insider selling and compress the premium. Singh has reshorted VCX around $300 and the shares have already fallen to $150.
HIGH
13:14
May 17
May 17
Avoid VCX due to excessive valuation premiums and dilution risk relative to NAV.
Avoid VCX due to excessive valuation premiums and dilution risk relative to NAV; consider direct private market alternatives instead.
HIGH
03:36
May 13
May 13
Bearish view on VCX as alleged forced selling of key AI holdings after SPV statements points.
Bearish view on VCX as alleged forced selling of key AI holdings after SPV statements points to deeper trouble; expect adverse press release or shareholder claims.
HIGH
14:45
May 12
May 12
The tweet discusses a legal strategy involving Section 12(g) and DGCL demands against DXYZ.
The tweet discusses a legal strategy involving Section 12(g) and DGCL demands against DXYZ and VCX, suggesting potential regulatory and disclosure risks for quasi-public markets.
LOW
13:58
May 12
May 12
Buy DXYZ/VCX at current market prices vs estimated NAVs.
Buy DXYZ/VCX at current market prices vs estimated NAVs; expect convergence as litigation/forced settlement delivers underlying shares or cash payouts, creating a low-risk arbitrage.
MED
01:21
May 06
May 06
The author notes lackluster Taiwan performance compared to the US and sarcastically lists.
The author notes lackluster Taiwan performance compared to the US and sarcastically lists specific stocks as the only ones worth holding, but provides no explicit forward-looking directional view.
HIGH
14:52
Apr 27
Apr 27
Avoid VCX due to premium risk
ETFs like the Fundrise ticker VCX trade at prices divorced from the underlying NAV (currently about 4x NAV). This means investors can lose money even if the companies perform well, especially in down markets. The product is better suited for trading sentiment on these names rather than as a direct venture investment.
MED
18:00
Apr 11
Apr 11
VCX is a beneficiary of the structural trend of private companies going public earlier.
VCX is a beneficiary of the structural trend of private companies going public earlier, as investor appetite for exposure to this theme is strong.
HIGH
16:36
Apr 10
Apr 10
Anthropic IPO demand exceeds SpaceX IPO demand.
VCX ETF, whose top holding is Anthropic, is up 250%+ since inception despite a 75% drawdown; author notes stronger public demand for an Anthropic IPO.
LOW
19:14
Apr 09
Apr 09
Stack Capital is highlighted as a high-performing.
Stack Capital is highlighted as a high-performing, undervalued private assets treasury poised for continued growth compared to overvalued peers.
17:28
Apr 02
Apr 02
VCX has a high borrow fee (800% rate), low float, and a share lockup period ending in September 2024. Its NAV is ~$20 vs. a share price ~$380. The lockup expiration will drastically increase the float, allowing restricted shareholders to sell, which should collapse the price toward NAV and has not been priced into October-dated options. Selling a call credit spread (Sell $70c / Buy $200c exp 10/17) profits if VCX is below $70 at expiration, which the author views as nearly guaranteed post-lockup. Early exercise on the short call (deemed irrational), a "miracle" business development that justifies a >3x NAV valuation, or option illiquidity causing poor fills.
HIGH
01:33
Mar 28
Mar 28
Expect downside in VCX due to its extreme premium to the net asset value of its underlying.
Expect downside in VCX due to its extreme premium to the net asset value of its underlying holdings.
MED
17:24
Mar 27
Mar 27
Ben Miller states his job is to deploy capital into the best tech companies, not to manage where the stock trades. He explicitly says he is "not allowed to say where I think it should trade" and that trading volatility "has nothing to do with me." The CEO's mandate is executing the fund's strategy of providing democratized access to private tech. The extreme premium/discount to NAV is a market pricing phenomenon separate from the fund's operational execution. NEUTRAL because the speaker, who controls the fund's investments, explicitly refrains from expressing a view on the stock's direction or valuation, focusing solely on the foundational business thesis. Market sentiment detaches completely from NAV, impacting the fund's ability to raise capital or continue operations. Persistent extreme premium could attract regulatory scrutiny.
11:15
Mar 27
Mar 27
Citron Research questions VCX's financial math and highlights extreme borrowing costs.
Citron Research questions VCX's financial math and highlights extreme borrowing costs as a warning to investors.
07:27
Mar 27
Mar 27
Fundrise Growth Tech Fund experiences a massive price surge following its recent NYSE listing.
HIGH
23:12
Mar 26
Mar 26
Citron Research has published a short report on $VCX, and the sponsor (Fundrise) filed to sell $23M of shares on the same day a critical report dropped, while most investors are locked up. This indicates the sponsor is exploiting a manufactured low-float, high-momentum situation to offload shares at inflated prices before the fundamental overvaluation corrects. The author views this as a clear short opportunity, expecting a ~90% collapse as the grift unravels, despite currently high short borrow fees. Extremely high borrow fee (~400% annualized, ~1% daily) could make holding the short position costly. A sustained short squeeze remains possible if buying pressure continues. The collapse thesis may take longer to materialize than expected.
HIGH
17:16
Mar 26
Mar 26
VCX plummeted over 40% as the author criticizes speculative hype-driven investing in private.
VCX plummeted over 40% as the author criticizes speculative hype-driven investing in private assets.
13:16
Mar 26
Mar 26
Citron Research predicts a potential 93% decline in VCX price if its premium compresses.
Citron Research predicts a potential 93% decline in VCX price if its premium compresses to match DXYZ levels.
13:16
Mar 26
Mar 26
Citron Research calls for an SEC investigation into potential undisclosed promotional payments.
Citron Research calls for an SEC investigation into potential undisclosed promotional payments by Fundrise for VCX.
13:16
Mar 26
Mar 26
Citron Research claims VCX is massively overvalued and highlights a history of SEC regulatory.
Citron Research claims VCX is massively overvalued and highlights a history of SEC regulatory violations.
HIGH
13:16
Mar 26
Mar 26
Citron Research highlights SEC charges against Fundrise for illegal paid solicitation practices.
About VCX Analyst Coverage
Buzzberg tracks VCX (Fundrise Innovation Fund, LLC) across 17 sources. 3 bullish vs 11 bearish calls from 17 analysts. Sentiment: mixed to bearish. 39 total trade ideas tracked. Past 7 days: 1 bullish, 1 watch. Latest voices: Ozark, Myles, Jay Singh.